Request Sample
Request Methodology
Description
Global Chagas Disease Management Market was valued at US$ 5.72 Mn in 2020 and is expected to witness a CAGR of 7.6% over the forecast period 2021-2027. Chagas disease or American trypanosomiasis is a tropical parasitic disease caused by Trypanosoma cruzi. Chagas disease is transmitted by kissing bugs or triatomine bugs. Chagas disease can also transmit through blood transfusions, mother to foetus during pregnancy, and sometimes it causes through organ transplantation. The symptoms of the Chagas disease in early stage include swollen lymph nodes, fever, headache, and local swelling at the site of the bite. The chronic symptoms will appear after 8-12 weeks that may include expansion of ventricles leads to the heart failure, oesophagus or colon may cause death. The diagnosis of Chagas disease is complicated, require laboratory analysis of blood samples for the detection of antibodies against the Trypanosome cruzi. The Chagas disease is majorly present in the Latin America and spreading to North America and Europe region. Increase in the Chagas disease population in Latin America region, rise in the prevalence of Chagas disease due to unhygienic conditions might fuel the growth of Chagas disease management market over the forecast period. In addition, increase in the research and development of new products are one of the main factors that drive the growth of chagas disease management market. However, lack of awareness regarding the chagas disease treatment, a limited number of approved products in the current market, and supply chain issues with chagas disease drugs will hamper the growth of the chagas disease management market over the forecast period. In March 2017, Daiichi Sankyo Company Limited and Drugs for Neglected Diseases initiative (DNDi) are collaborated to form a joint research with regard to a new research program, the hit-to-lead project to develop the drugs for Chagas disease and leishmaniasis
